We sincerely thank

- The Foundation Johanna Dümmüller-Bol
- Stem Cell Research and Regenerative Medicine (SCRM) and Alumni Med Bern
- Prize and Award Committees
- Unitectra, Innovation Office (unibe), Grants Office (unibe) and the FELS Network
- Researchers, Students, Colleagues, and all participants

for supporting us and making the DBMR Day of BioMedical Research possible!
Prof. Dr. Hans Clevers is a Dutch molecular geneticist, cell biologist and stem cell researcher. He is currently the Head of pharma Research and Early Development (pRED), and a member of the Corporate Executive Committee of F. Hoffmann-La Roche based in Basel, Switzerland. Previously, Prof. Dr. Hans Clevers headed a research group at the Hubrecht Institute for Developmental Biology and Stem Cell Research, and at the Princess Máxima Center for Pediatric Oncology and Oncode where he remained as an advisor and guest scientist or visiting researcher. He is also a Professor in Molecular Genetics at the University of Utrecht (NL).

Prof. Dr. Hans Clevers also served at a number of scientific organizations, including on the Board of Directors of the American Association for Cancer Research, and the Scientific Advisory Board of the Swiss Institute for Experimental Cancer Research at the École Polytechnique Fédérale de Lausanne, the Research Institute of Molecular Pathology in Vienna and the Francis Crick Institute in London. He is currently on many Prize Juries (e.g. Francqui Prize, Brussels; Breakthrough Prize, San Francisco) and also the advisory board of various scientific journals, including the EMBO Journal, Disease Models & Mechanisms, Cell, Stem Cell Reports, Cell Stem Cell, and EMBO Molecular Medicine. From 2014 to 2022, he was also on the editorial committee of the Annual Review of Cancer Biology. He has published over 740, highly cited, peer-reviewed papers. Outside of academia, Prof. Dr. Hans Clevers was also a scientific advisor to numerous biotechnology companies and co-founded California-based Surrozen in 2016 and Shanghai-based D1 Medical Technology in 2019.